Evidence map›Paper›PMID 34762551›Full record

ArticleHuman vaccines & immunotherapeutics2021

TIPICO XI: report of the first series and podcast on infectious diseases and vaccines (aTIPICO).

Federico Martinón-Torres, Adolfo García-Sastre, Andrew J Pollard, Carlos Martín, Albert Osterhaus, Shamez N Ladhani, Octavio Ramilo, Jose Gómez Rial, Antonio Salas, F Xavier Bosch and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Federico Martinón-TorresDepartment of Paediatrics Translational Paediatrics and Infectious Diseases, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain.ORCID 0000-0002-9023-581X
Adolfo García-SastreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Andrew J PollardOxford Vaccine Group, Department of Paediatrics, Universidad de Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
Carlos MartínDepartment of Microbiology, Faculty of Medicine, IIS Aragon, Universidad de Zaragoza, CIBERES, Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0003-2993-5478
Albert OsterhausResearch Center Emerging Infections and Zoonoses (RIZ, University of Veterinary Medicine Hannover, Hannover, Germany.
Shamez N LadhaniPublic Health England, London, UK.ORCID 0000-0002-0856-2476
Octavio RamiloNationwide Children's Hospital and the Ohio State University, Columbus, Ohio, US.
Jose Gómez RialImmunology Department, Hospital Clínico Universitario de Santiago de Compostela, Spain.
Antonio SalasUnidade de Xenética, Instituto de Ciencias Forenses (INCIFOR), Facultade de Medicina, Universidade de Santiago de Compostela, and GenPoB Research Group, Instituto de Investigacinó Sanitaria (IDIS), Hospital Clínico Universitario de Santiago (SERGAS), Galicia, Spain.ORCID 0000-0002-2336-702X
F Xavier BoschInstitut Catalá de Oncología, Barcelona, Spain.
María Martinón-TorresCENIEH (National Research Center on Human Evolution), Burgos, Spain.
Michael J MinaHarvard School of Public Health and Harvard Medical School, Boston, MA, US.
James CherryThe David Geffen School of Medicine at UCLA, Los Angeles, CA, US.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TIPiCO is an annual expert meeting and workshop on infectious diseases and vaccination. The edition of 2020 changed its name and format to aTIPiCO, the first series and podcasts on infectious diseases and vaccines. A total of 13 prestigious experts from different countries participated in this edition launched on the 26 November 2020. The state of the art of coronavirus disease-2019 (COVID-19) and the responsible pathogen, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and the options to tackle the pandemic situation were discussed in light of the knowledge in November 2020. Despite COVID-19, the status of other infectious diseases, including influenza infections, respiratory syncytial virus disease, human papillomavirus infection, measles, pertussis, tuberculosis, meningococcal disease, and pneumococcal disease, were also addressed. The essential lessons that can be learned from these diseases and their vaccines to use in the COVID-19 pandemic were also commented with the experts.

Indexed as

Communicable DiseasesCOVID-19Influenza VaccinesHumansPandemicsSARS-CoV-2Influenza Vaccinescontrol of transmissionCOVID-19 pandemicInfectious diseasesevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2)vaccine-immunity responsevaccine-preventable disease

Identifiers

PMID34762551
PMCPMC8828069

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.